{"Clinical Trial ID": "NCT00475670", "Intervention": ["INTERVENTION 1:", "Trastuzumab monotherapy", "Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV on day 1, followed by 2 mg/kg, IV once weekly, or an initial loading dose of 8 mg/kg IV on day 1, followed by 6 mg/kg IV once every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.", "INTERVENTION 2:", "Trastuzumab, Taxane", "Participants received either an initial loading dose of trastuzumab 4 mg/kg IV on day 1, followed by 2 mg/kg IV once a week, or an initial loading dose of 8 mg/kg IV on day 1, followed by 6 mg/kg IV every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. Participants also received one of the following taxanes (at the discretion of the investigator) for at least 18 weeks: docetaxel 100 mg/m^2, IV once every 3 weeks, OR, paclitaxel 75 mg/m^2, IV once a week, OR, paclitaxel 175 mg/m^2, IV once every 3 weeks."], "Eligibility": ["Incorporation criteria:", "At least 10 months of Herceptin treatment for HER2-positive early breast cancer;", "Metastatic breast cancer >=12 months after herceptin discontinuation;", "A measurable disease.", "- Exclusion criteria:", "Previous chemotherapy for metastatic breast cancer;", "- brain metastases;", "Invasive malignancy other than metastatic breast cancer."], "Results": ["Performance measures:", "Percentage of participants receiving a complete (RC) or partial (PR) response according to the solid tumour response assessment criteria (RECIST) Version 1.0 Guidelines", "The CR was defined for target lesions (TL) as the removal of all lesions, and for non-target lesions (NTLs) as the removal of all non-measurable lesions that were not targeted. PR was defined for LT as a decrease of at least 30 percent (%) from the inclusion (BL) of the sum of the longest diameter (LDS) of LT. 95% confidence interval for a binomial sample using the Pearson-Clopper method.", "Time frame: baseline; day 1 of weeks 7, 13, 19, 25, 37 and 52, at the last dose of study treatment, every 24 weeks thereafter until disease progression lasts up to 6 months after recruitment of the last participant", "Results 1:", "Title of the arm/group: Trastuzumab monotherapy", "The participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on day 1, followed by 2 mg/kg, IV, once weekly, or an initial loading dose of 8 mg/kg, IV, on day 1, followed by 6 mg/kg, IV, once every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.", "Total number of participants analysed: 0", "Type of measurement: Number", "Unit of measure: percentage of participants", "Results 2:", "Title of the arm/group: Trastuzumab, Taxane", "The participants received either an initial loading dose of trastuzumab 4 mg/kg IV on day 1, followed by 2 mg/kg IV once weekly, or an initial loading dose of 8 mg/kg IV on day 1, followed by 6 mg/kg IV every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death. Participants also received one of the following taxanes (at the discretion of the investigator) for at least 18 weeks: docetaxel 100 mg/m^2, IV, once every 3 weeks, OR, paclitaxel 75 mg/m^2, IV, once weekly, OR, paclitaxel 175 mg/m^2, IV, once every 3 weeks.", "Total number of participants analysed: 41", "Type of measurement: Number", "Unit of measure: % of participants 61.0 (48.7 to 80.4)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/3 (0.00 per cent)", "Febrile Neutropenia * 0/3 (0.00 %)", "Neutropenia * 0/3 (0.00 %)", "- Sudden death * 0/3 (0.00 %)", "Bacterial infection * 0/3 (0.00 %)", "Bronchite * 0/3 (0.00 %)", "Sepsis * 0/3 (0.00 %)", "- Lymphedema * 0/3 (0.00 %)", "Adverse Events 2:", "Total: 6/41 (14.63%)", "- Neutropenia * 1/41 (2.44 per cent)", "Neutropenia * 1/41 (2.44%)", "* 1/41 (2.44 per cent)", "Bacterial infection * 1/41 (2.44 per cent)", "Bronchite * 1/41 (2.44%)", "\u2022 Sepsis * 1/41 (2.44%)", "* 1/41 (2.44%)"]}